Ernexa Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
| ITEM 9B. | Other Information |
|---|
During the quarter ended December 31, 2025, no director or officer of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
On March 10, 2026, the Compensation Committee approved increases to the compensation of our President and Chief Executive Officer, Sanjeev Luther, and our Senior Vice President of Finance, Sandra Gurrola, effective April 1, 2026. Mr. Luther’s annual base salary increased from $550,000 to $670,000. Ms. Gurrola’s annual base salary increased from $275,000 to $300,000. Additionally, the Committee approved a bonus payment for Ms. Gurrola in the amount of $68,000 and a bonus in the amount of $319,000 for Mr. Luther. There were no other changes to any other component of Mr. Luther’s or Ms. Gurrola’s executive compensation under our compensation plans and programs as previously disclosed.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.